JILL HARRISON: Open Payments
NPI 1518192293 · PLYMOUTH, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$317 in 15 payments from 9 companies in 2025. Trend: 2023 $27 · 2024 $646 · 2025 $317
Food & beverage: $317
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| ABBVIE INC. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
Products named: INGREZZA, VRAYLAR, REXULTI, ABILIFY ASIMTUFII, AUSTEDO XR, CAPLYTA, ARISTADA, Jornay PM.
Industry payments across MA — which companies pay providers there.
